Scott Pinter, MD
Ophthalmology · Bloomington, ILNPI 1174527626
Payments from drug & device makers
Across 180 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$631
- Novartis$447
- AbbVie$308
- Rxsight Inc$266
- Bausch & Lomb Americas Inc.$214
- Glaukos Corporation$198
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$3,45397%
- Other$812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 24 | $631 |
| Novartis | 32 | $447 |
| AbbVie(2 entities) | 25 | $308 |
| Rxsight Inc | 10 | $266 |
| Bausch & Lomb Americas Inc. | 11 | $214 |
| Glaukos Corporation | 8 | $198 |
| Mallinckrodt Hospital Products Inc. | 7 | $177 |
| Harrow Eye, LLC | 7 | $171 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $120 |
| Sun Pharmaceutical Industries Inc. | 6 | $114 |
| Astellas Pharma US Inc | 4 | $114 |
| Oyster Point Pharma, Inc. | 6 | $112 |
| Tarsus Pharmaceuticals, Inc. | 6 | $110 |
| Genentech USA, Inc. | 4 | $77 |
| Amgen(2 entities) | 4 | $74 |
| Apellis Pharmaceuticals, Inc. | 3 | $74 |
| Shire North American Group Inc | 2 | $54 |
| Kala Pharmaceuticals, Inc. | 3 | $49 |
| Dompe US, Inc. | 2 | $47 |
| Aerie Pharmaceuticals, Inc. | 3 | $42 |
| Thea Pharma Inc. | 2 | $40 |
| Johnson & Johnson Vision Care, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $25 |
| Quidel Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$131
How this compares
$3,559 in reported general payments places this provider in the 70th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $40,350 |
| XiidraLifitegrast | 24 | $39,409 |
| LumiganBimatoprost | 49 | $31,268 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $13,188 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $6,313 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $5,858 |
| Cyclosporine | 12 | $4,596 |
| Latanoprost | 334 | $3,387 |
| Prednisolone Acetate | 70 | $2,189 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 119 | $2,138 |
| Brimonidine Tartrate | 36 | $2,102 |
| Timolol Maleate | 138 | $1,311 |
| Gatifloxacin | 18 | $586 |
| Doxycycline Hyclate | 23 | $557 |
| Ketorolac Tromethamine | 26 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $308 | $71,61888 claims |
| Bausch & Lomb Americas Inc.Xiidra | $214 | $39,40924 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $42 | $13,18814 claims |
| AlconSimbrinza | $631 | $6,31316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Bloomington
- Veeral ShethOak Forest$14.8M
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.9M
- Manjot GillChicago$1.4M
- Mitchell JacksonLake Villa$1.4M
- Ramanath BhandariSpringfield$1.2M
- Kathleen MornoNorth Riverside$1.2M
- Amani FawziChicago$864K
- Navaneet Chailert BorisuthRock Island$737K
- David LubeckHomewood$709K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.